Sinergium Biotech has announced it will begin construction of a new primary antigen production plant in the town of Garin, which is located in the province of Buenos Aires, Argentina.
JN-International Medical Corporation (JNI), a US-based private biopharmaceutical corporation, develops infectious disease vaccines and diagnostics.
Founded in 1997 by Dr Jeeri R Reddy in rural Oakland, Nebraska, JNI expanded and moved to Omaha, Nebraska, in 2000. In 2009 JNI acquired Pfizer’s Biocor EU/cGMP facilities in Omaha for research, development and manufacture of human vaccines.
Meningococcal meningitis vaccines
Offices and clinical trial centers are in Abidjan, Ivory Coast and Kuala Lumpur (Malaysia), with vaccine cold-chain facilities in Burkina Faso and Singapore. JNI is an Inc 5000 company – the 95th-ranking US company and third-ranking global biopharmaceutical corporation producing Meningococcal meningitis vaccines.
JNI has international intellectual property rights and patents granted in the US for Meningococcal meningitis serogroups A, C, Y and W-135 plain polysaccharide and diphtheria toxoid conjugate vaccines. The strategic vision of JNI is to use novel 21st century technologies for cost-effective vaccine production and generation of innovative vaccines for prevention of common diseases.
JN-International Medical Corporation
Pipeline vaccines against stroke, Parkinson’s, Alzheimer’s, Huntington’s disease, hepatitis C and genital herpes
JNI has patents filed in the US and worldwide for potential vaccines against stroke, Parkinson’s, Alzheimer’s, Huntington’s disease, hepatitis C and genital herpes. We are seeking collaborative partnerships within industry and academia partners for developing these pipeline vaccines.
With over a decade of delivering on the promise of biotechnology and strength in all areas of product development, including research, manufacturing and commercialization, JNI continues to transform biotechnological possibilities, including genetic engineering technology, into improved human health.
High-quality vaccines and diagnostics for infectious disease
JNI commits to high standards of integrity and to meeting the best interests of international communities, seeking significant returns based on pursuit of scientific and operational excellence. For more than a decade the name JNI has been synonymous with high-quality, innovative products, sound business strategy, and a passion for people around the world who receive our products.
Emphasis on basic research combined with an applied focus on unequivocal medical needs was instrumental to success and growth. These priorities are the blueprint upon which JNI was built and will continue to grow.
Infectious disease vaccines for developing countries
JNI partners with multiple non-profit global health organizations, NGOs, local governments and communities to address health issues related to infectious diseases that scourge underserved communities in Africa, South East Asia and Latin America.